Epratuzumab is an investigational antibody designed to help treat SLE. The purpose is to evaluate safety and long term efficacy in concert with standard SLE treatments
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
The primary objective is to continue to gather long term safety data on patients with moderate to severe flaring SLE.
To continue to assess the efficacy and tolerability of epratuzumab;
To continue to monitor the plasma concentration and immunogenicity profile of epratuzumab in patients with Lupus;
To continue to assess epratuzumab on Health-related quality of life in lupus patients;
To continue to assess disease status as reported by the patient and physician.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Birmingham, Alabama, United States
Unnamed facility
Tucson, Arizona, United States
Unnamed facility
Los Angeles, California, United States
Unnamed facility
Upland, California, United States
Unnamed facility
Farmington, Connecticut, United States
Unnamed facility
Washington D.C., District of Columbia, United States
Unnamed facility
Aventura, Florida, United States
Unnamed facility
Chicago, Illinois, United States
Unnamed facility
Baltimore, Maryland, United States
Unnamed facility
New York, New York, United States
...and 44 more locations